(PubMed) Checchi S, Montanaro A, Ciuoli C, et al
[DOI] [PubMed] [Google Scholar] 43.Wakamatsu T.H., Dogru M., Matsumoto Y., Kojima T., Kaido M., Ibrahim O.M., Sato E.A., Igarashi A., Ichihashi Y., Satake Y., et al
This decision reverses a previous ruling that placed approximately 19 peptides on the more restrictive Category 2 list, effectively banning their use in compounded medications due to potential significant safety risks. The reversal came after significant debate and legal challenges from medical providers and pharmacy groups, who argued that the FDA had not presented sufficient evidence to justify the ban
Reduced default mode network functional connectivity in patients with recurrent major depressive disorder